Intuitive Surgical, Inc. (NASDAQ:ISRG) Q3 2024 Earnings Conference Call

For the period ending March 31, 2022

October 17, 2024 4:30 p.m. ET

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Thank you everyone for standing by and welcome to the Intuitive Third Quarter 2024 Earnings Release. Now at this time all participants are on a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions]

I will now turn the conference over to your host, Brandon Lamb within Investor Relations for Intuitive. Please go ahead.

Brandon Lamb

Good afternoon and welcome to Intuitive’s third quarter earnings conference call. With me today we have Gary Guthart, our CEO; Dave Rosa, our President; and Jamie Samath, our CFO.

Before we begin, I would like to let you know that Brian King has moved on to pursue his next opportunity. We appreciate his contributions over the past nine years and wish him well in his next endeavor. A search for his replacement is in progress.

Moving on, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in our Securities and Exchange Commission filings including our most recent Form 10-K where the fiscal year ended December 31, 2023, and subsequent filings. Our SEC filings can be found through our website or at the SEC's website.

Investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at intuitive.com on the events section under our investor relations page.

Today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our third quarter results as described in our press release announced earlier today followed by a question-and-answer session. Gary will introduce the call and provide a business overview; Dave will present the quarter's business, operational, and clinical highlights; Jamie will provide a review of our financial results and procedure highlights. Then I will provide our updated financial outlook for 2024. And finally, we will host a question-and-answer session.

With that I will turn it over to Gary.

Gary Guthart

Thank you for joining us today. Q3 of 2024 was a good quarter for us with healthy procedure growth, solid capital placements and strong operational execution in a dynamic global environment.